Cargando…
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514538/ https://www.ncbi.nlm.nih.gov/pubmed/28716097 http://dx.doi.org/10.1186/s40425-017-0259-9 |
_version_ | 1783250860261769216 |
---|---|
author | Moreira, Raphael B. Hamieh, Lana Gjini, Evisa Lako, Ana Krajewski, Katherine M. Yoon, Charles H. Ott, Patrick A. |
author_facet | Moreira, Raphael B. Hamieh, Lana Gjini, Evisa Lako, Ana Krajewski, Katherine M. Yoon, Charles H. Ott, Patrick A. |
author_sort | Moreira, Raphael B. |
collection | PubMed |
description | BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. CONCLUSION: The exact cause of our patient’s sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response. |
format | Online Article Text |
id | pubmed-5514538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55145382017-07-19 Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab Moreira, Raphael B. Hamieh, Lana Gjini, Evisa Lako, Ana Krajewski, Katherine M. Yoon, Charles H. Ott, Patrick A. J Immunother Cancer Case Report BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. CONCLUSION: The exact cause of our patient’s sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response. BioMed Central 2017-07-18 /pmc/articles/PMC5514538/ /pubmed/28716097 http://dx.doi.org/10.1186/s40425-017-0259-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Moreira, Raphael B. Hamieh, Lana Gjini, Evisa Lako, Ana Krajewski, Katherine M. Yoon, Charles H. Ott, Patrick A. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title | Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title_full | Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title_fullStr | Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title_full_unstemmed | Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title_short | Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
title_sort | regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514538/ https://www.ncbi.nlm.nih.gov/pubmed/28716097 http://dx.doi.org/10.1186/s40425-017-0259-9 |
work_keys_str_mv | AT moreiraraphaelb regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT hamiehlana regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT gjinievisa regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT lakoana regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT krajewskikatherinem regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT yooncharlesh regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab AT ottpatricka regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab |